Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Male Urogenital Diseases 3Prostatic Intraepithelial Neoplasia 2Uremia 1Prostatic Hyperplasia 1Neoplasms 1Neoplasm Metastasis 1Disease Progression 1Colorectal Cancer Metastatic 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 91Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 23Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × Lycopene × Clear all
NCT00172367 2008-09-26

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

National Taiwan University Hospital

Phase 2 Withdrawn
80 enrolled
Genitourinary

Carcinoma, Transitional Cell, Uremia, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡